ArticleJournal of experimental & clinical cancer research : CR2025
Novel APLNR antagonist candesartan induces tumor vascular normalization through ROS/cGAS/STING axis and augmented sunitinib response in breast cancer.
Chenyu Liang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.